Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies

Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies

Bibliographic Details
Main Authors:	Stephan, Rosenkranz, Ghofrani, Hossein-Ardeschir, Beghetti, Maurice, Ivy, Dunbar, Fritsch, Arno, Weimann, Gerrit, Saleh, Soundos, Apitz, Christian, Frey, Reiner
Format:	Online
Language:	English
Published:	BioMed Central 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565076/

Similar Items

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
by: Rosenkranz, Stephan, et al.
Published: (2015)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
by: Ghofrani, Hossein A, et al.
Published: (2009)

The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT)
by: Huntgeburth, Michael, et al.
Published: (2015)

Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
by: Becker, Corina, et al.
Published: (2013)

Effects of omeprazole and AlOH/MgOH on riociguat absorption
by: Becker, Corina, et al.
Published: (2013)

Riociguat: PATENT-1 Study
by: Said, Karim
Published: (2014)

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
by: Frey, Reiner, et al.
Published: (2009)

Effects of riociguat in severe experimental pulmonary hypertension
by: Kojonazarov, Baktybek, et al.
Published: (2011)

Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food
by: Saleh, Soundos, et al.
Published: (2015)

Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison
by: Wang, Chen, et al.
Published: (2016)

Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
by: Frey, Reiner, et al.
Published: (2013)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
by: Lang, Michaela, et al.
Published: (2011)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
by: Frey, Reiner, et al.
Published: (2011)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
by: Frey, Reiner, et al.
Published: (2013)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
by: Frey, Reiner, et al.
Published: (2013)

Absorption behavior of riociguat: bioavailability, food effects, and dose-proportionality
by: Becker, Corina, et al.
Published: (2013)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
by: Lang, Michaela, et al.
Published: (2012)

The clinical development of sGC modulators, riociguat and vericiguat
by: Misselwitz, Frank
Published: (2015)

Riociguat: Something new in pulmonary hypertension therapeutics?
by: Shanmugam, Elangovan, et al.
Published: (2015)

MONOUNSATURATES AND CHD
Published: (1989)

Oral health status of CHD and non-CHD adults of Lahore, Pakistan
by: Bokhari, Syed Akhtar Hussain, et al.
Published: (2011)

CHD1 and CHD2 are positive regulators of HIV-1 gene expression
by: Rodgers, Melissa J, et al.
Published: (2014)

The molecular targets of approved treatments for pulmonary arterial hypertension
by: Humbert, Marc, et al.
Published: (2016)

Biodegradation of Mixed PAHs by PAH-Degrading Endophytic Bacteria
by: Zhu, Xuezhu, et al.
Published: (2016)

Photosensitivity and CHD2 Variants
by: Sosa, Rebecca García, et al.
Published: (2015)

Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction: Study protocol for a randomized controlled trial
by: Mascherbauer, Julia, et al.
Published: (2016)

Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat
by: Smith, Zachary R, et al.
Published: (2016)

Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1): A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study
by: Bonderman, Diana, et al.
Published: (2014)

Heart Rate Variability is Related to Disease Severity in Children and Young Adults with Pulmonary Hypertension
by: Latus, Heiner, et al.
Published: (2015)

Walking the tightrope of bioavailability: growth dynamics of PAH degraders on vapour‐phase PAH
by: Hanzel, Joanna, et al.
Published: (2012)

Multimedia Model for Polycyclic Aromatic Hydrocarbons (PAHs) and Nitro-PAHs in Lake Michigan
by: Huang, Lei, et al.
Published: (2014)

PAH cleanup in Illinois.
by: O'Brien, J P
Published: (1994)

Identification and Characterization of FAM124B as a Novel Component of a CHD7 and CHD8 Containing Complex
by: Batsukh, Tserendulam, et al.
Published: (2012)

Differential Expression and Sex Chromosome Association of CHD3/4 and CHD5 during Spermatogenesis
by: Bergs, Judith W., et al.
Published: (2014)

Green tea consumption is associated with reduced incident CHD and improved CHD-related biomarkers in the Dongfeng-Tongji cohort
by: Tian, Chong, et al.
Published: (2016)

Editorial: Pediatric Pulmonary Hypertension
by: Beghetti, Maurice, et al.
Published: (2015)

Calponin-Like Chd64 Is Partly Disordered
by: Kozłowska, Małgorzata, et al.
Published: (2014)

CHD1L: a novel oncogene
by: Cheng, Wen, et al.
Published: (2013)

Silencing of CHD5 Gene by Promoter Methylation in Leukemia
by: Zhao, Rui, et al.
Published: (2014)

Transcription regulation by CHD proteins to control plant development
by: Hu, Yongfeng, et al.
Published: (2014)